CNNM3: Potential Drug Targets and Biomarkers (G26505)

Target Name: CNNM3

NCBI ID: G26505

CNNM3

CNNM3: Potential Drug Targets and Biomarkers

CNNM3 (Cyclin and CBS domain divalent metal cation transport mediator 3) is a protein that plays a crucial role in the regulation of mitochondrial function and metabolism. It is a member of the cyclin family, which includes proteins that regulate the length of the cell's chromosomes. In addition to its role in regulating mitochondrial function, CNNM3 has also been shown to play a key role in the regulation of cellular signaling pathways that are involved in a wide range of biological processes, including cell division, metabolism, and stress resistance.

The research on CNNM3 has led to the identification of potential drug targets and biomarkers for a variety of diseases, including cancer, neurodegenerative diseases, and metabolic disorders. In this article, we will review the current state of research on CNNM3 and its potential as a drug target.

Potential Drug Targets

CNNM3 has been shown to play a key role in a variety of cellular signaling pathways that are involved in the development and progression of a wide range of diseases. Its role in these processes makes it an attractive target for drug development.

One of the most promising potential drug targets for CNNM3 is its role in the regulation of cell division. CNNM3 has been shown to play a key role in the regulation of mitochondrial fusion, which is the process by which new chromosomes are copied and inserted into the mitochondria. In addition, CNNM3 has also been shown to play a role in the regulation of cell division in cancer cells.

Another potential drug target for CNNM3 is its role in the regulation of metabolism. CNNM3 has been shown to play a key role in the regulation of mitochondrial metabolism, including the production of energy and the regulation of the levels of different nutrients in the body. In addition, CNNM3 has also been shown to play a role in the regulation of cellular signaling pathways that are involved in metabolism, including the regulation of fuel metabolism and the regulation of insulin sensitivity.

In addition to its role in cell division and metabolism, CNNM3 has also been shown to play a key role in the regulation of stress resistance. It has been shown to play a role in the regulation of the production of stress-induced signaling pathways, including the regulation of the production of reactive oxygen species (ROS).

Potential Biomarkers

The regulation of CNNM3 activity by drug treatment has the potential to serve as a biomarker for a variety of diseases. For example, changes in CNNM3 activity levels have been observed in a variety of cancer types, including breast, ovarian, and colorectal cancers. In addition, changes in CNNM3 activity levels have also been observed in neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

In addition to its potential as a biomarker, CNNM3 has also been shown to play a key role in the development of certain diseases. For example, studies have shown that changes in CNNM3 activity levels are associated with the development of certain types of cancer, including breast and ovarian cancers. In addition, changes in CNNM3 activity levels have also been associated with the development of certain neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

Conclusion

In conclusion, CNNM3 is a protein that plays a crucial role in the regulation of mitochondrial function and metabolism. Its role in these processes makes it an attractive target for drug development, and its potential as a biomarker for a variety of diseases makes it an important area of research. Further studies are needed to fully understand the role of CNNM3 in these processes and its potential as a drug target and biomarker.

Protein Name: Cyclin And CBS Domain Divalent Metal Cation Transport Mediator 3

Functions: Probable metal transporter

The "CNNM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNNM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets